Financial Results for the 3rd Quarter Ended 31st March 2026 - 29/04/2026
Filed with PSX · · 25 pages · English and Arabic
Summary by 6ix AI
The report indicates that the company recorded an increase in revenue compared to the same period last year, although it still faced an operating loss. The management remains focused on improving operational efficiency and controlling costs while navigating industry challenges.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Liven Pharma
- Board Meeting for the 3rd Quarter Financials of 2025-26 - 23/04/2026
- Condensed Interim Financial Statements for the Half Year ended December 31, 2025 (with shariah compliant disclosure) - 09/03/2026
- Liven Pharma: Condensed Interim Financial Statements for the Half Year ended December 31, 2025 (with shariah compliant disclosure)
- Condensed Interim Financial Statements for the Half Year ended December 31, 2025. - 27/02/2026
- Liven Pharma: Condensed Interim Financial Statements for the Half Year ended December 31, 2025.
Later from Liven Pharma
- Board Meeting - 25/09/2026
- Annual Free-Float Certificate duly verified by the Auditor REVOKED - 05/10/2026
- Correction Clarification Regarding Annual Report 2026 - 05/10/2026
- financial results for the Year Ended June 30, 2026 - 05/10/2026
- Notice of Annual General Meeting REVISED - 05/10/2026
Follow Liven Pharma into a list and get an email when it puts out news.
Follow Liven Pharma